Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Bausch + Lomb Corp (BLCO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: BLCO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $14.29
1 Year Target Price $14.29
| 3 | Strong Buy |
| 3 | Buy |
| 8 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.71% | Avg. Invested days 32 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.92B USD | Price to earnings Ratio - | 1Y Target Price 14.29 |
Price to earnings Ratio - | 1Y Target Price 14.29 | ||
Volume (30-day avg) 15 | Beta 0.56 | 52 Weeks Range 10.45 - 21.69 | Updated Date 07/12/2025 |
52 Weeks Range 10.45 - 21.69 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -7.5% | Operating Margin (TTM) -5.37% |
Management Effectiveness
Return on Assets (TTM) 0.61% | Return on Equity (TTM) -5.36% |
Valuation
Trailing PE - | Forward PE 25.45 | Enterprise Value 9532572245 | Price to Sales(TTM) 1.02 |
Enterprise Value 9532572245 | Price to Sales(TTM) 1.02 | ||
Enterprise Value to Revenue 1.98 | Enterprise Value to EBITDA 19.01 | Shares Outstanding 353396992 | Shares Floating 41707873 |
Shares Outstanding 353396992 | Shares Floating 41707873 | ||
Percent Insiders 88.17 | Percent Institutions 11.01 |
Upturn AI SWOT
Bausch + Lomb Corp
Company Overview
History and Background
Bausch + Lomb was founded in 1853 in Rochester, New York, by John Jacob Bausch and Henry Lomb. Initially a small optical goods store, it grew to become a global leader in eye health products, including contact lenses, lens care products, pharmaceuticals, and surgical devices. It has been involved in many eye health milestones and has undergone multiple changes in ownership.
Core Business Areas
- Vision Care: Develops, manufactures, and markets a broad range of contact lenses and lens care products, including daily disposable, reusable, and specialty contact lenses.
- Ophthalmic Pharmaceuticals: Offers a wide array of prescription and over-the-counter ophthalmic pharmaceuticals, including treatments for glaucoma, dry eye, and other eye conditions.
- Surgical: Provides surgical devices, instruments, and technologies for cataract and refractive surgery.
Leadership and Structure
Brent Saunders serves as the Chairman and CEO. The company has a typical corporate structure with various departments reporting to the executive team.
Top Products and Market Share
Key Offerings
- ULTRA Contact Lenses: Monthly disposable contact lenses known for comfort and moisture retention. Competitors include Alcon's Air Optix and CooperVision's Biofinity. Market share data is proprietary, but ULTRA is considered a leading brand in the monthly lens category. Revenue from this product is proprietary. Competitors: Alcon, Johnson & Johnson, CooperVision
- Biotrue ONEday Contact Lenses: Daily disposable contact lenses that mimic the natural moisture of the eye. Competitors include Alcon's Dailies Total1 and Johnson & Johnson's 1-Day Acuvue Moist. Market share data is proprietary, but Biotrue ONEday is a significant player in the daily lens market. Revenue from this product is proprietary. Competitors: Alcon, Johnson & Johnson, CooperVision
- Lumify: Over-the-counter eye drops that reduce redness. Competitors include Visine and Clear Eyes. Market share data indicates Lumify holds a significant portion of the redness reliever market. Revenue from this product is proprietary. Competitors: Visine, Clear Eyes
Market Dynamics
Industry Overview
The eye health market is driven by an aging population, increasing prevalence of eye conditions (e.g., myopia, dry eye), and technological advancements in vision correction. It is a growing market with strong demand for contact lenses, ophthalmic pharmaceuticals, and surgical solutions.
Positioning
Bausch + Lomb is a major player in the eye health industry, with a broad product portfolio and a strong brand reputation. It competes with other large companies but maintains a competitive advantage through innovation and established market presence.
Total Addressable Market (TAM)
The global eye care market is estimated to be worth hundreds of billions of dollars. Bausch + Lomb is positioned to capture a significant portion of this TAM through its diverse product offerings and global reach.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Broad product portfolio
- Global distribution network
- Established market presence
- Strong R&D capabilities
Weaknesses
- High debt levels
- Exposure to generic competition in pharmaceuticals
- Dependence on key products
- Slower growth in certain segments
Opportunities
- Expanding into emerging markets
- Developing innovative products and technologies
- Acquiring complementary businesses
- Capitalizing on the growing demand for eye health products
Threats
- Intense competition
- Regulatory changes
- Economic downturns
- Technological disruptions
- Patent expirations
Competitors and Market Share
Key Competitors
- ALC
- JNJ
- COO
Competitive Landscape
Bausch + Lomb competes with other major players in the eye health industry. Each competitor has strengths in different products or areas that contribute to the competitive landscape.
Major Acquisitions
DiaMedica Therapeutics Inc.
- Year: 2024
- Acquisition Price (USD millions): 775
- Strategic Rationale: Enhance pharmaceutical offerings in the retina segment.
Growth Trajectory and Initiatives
Historical Growth: Bausch + Lomb's historical growth has been influenced by factors such as acquisitions, product launches, and market conditions.
Future Projections: Future growth projections are based on analyst estimates. Refer to financial data for current information
Recent Initiatives: Recent strategic initiatives include focusing on core product areas, investing in R&D, and expanding into emerging markets.
Summary
Bausch + Lomb is a significant player in the eye health market with a rich history and a diverse product portfolio. Its strong brand recognition and global reach are key strengths. However, it faces challenges such as high debt and intense competition. The company can capitalize on growth opportunities through innovation and expansion into emerging markets, but it must also navigate regulatory hurdles and technological disruptions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Market research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change, so you should always consult with a financial professional before making any investment decisions. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bausch + Lomb Corp
Exchange NYSE | Headquaters Vaughan, ON, Canada | ||
IPO Launch date 2022-05-06 | CEO & Chairman Mr. Brenton L. Saunders J.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 13500 | Website https://www.bausch.com |
Full time employees 13500 | Website https://www.bausch.com | ||
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.